This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AC137
Description: BioMedTracker has separate drug profiles for the Symlin and Symlin in combination with metreleptin and Symlin in combination with insulin. Please also see Symlin and Metreleptin and Symlin and Insulin.
Symlin is an amylin analog. Amylin is a hormone secreted with insulin by pancreatic b cells. Its physiologic effects include augmenting insulin action at multiple levels of metabolism including glucose control and other aspects of energy utilization. Preclinical investigation discovered amylin acts as a neuroendocrine hormone that complements insulin effects in postprandial glucose regulation by suppressing postprandial glucagon secretion and slowing the rate of nutrient delivery from the stomach to the small intestine.
Amylin and/or its effects can be missing or diminished in diabetes mellitus, much in the same way that insulin or insulin sensitivity is lost. Human amylin is not optimal for replacement therapy for various biochemical reasons. Therefore, pramlintide, a soluble, nonaggregating synthetic peptide analog of human amylin, was developed. Pramlintide, the active ingredient of Symlin, has potency at least equal to that of human amylin.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Amylin was previously developing Symlin with Johnson & Johnson. JNJ inexplicably abandoned its role in Symlin development in 1998.
Amylin and Eli Lilly
The Sept 2002 agreement between Amylin and Eli Lilly focused on AC2993 suggests that Amylin will not seek a partner for Symlin because the agreement states that Lilly will help Amylin develop its sales force in anticipation of Symlin marketing.
Amylin and Bristol-Myers Squibb
Bristol-Myers Squibb and Amylin announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion. The total value of the transaction, including Amylin's net debt and a contractual payment obligation to Eli Lilly & Company, together totaling about $1.7 billion, is approximately $7 billion. The acquisition has been unanimously approved by the...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
Symlin (Pramlintide) News
Pink Sheet Symlin titration trial
Additional information available to subscribers only: